# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated wi...
RBC Capital analyst Brian Abrahams reiterates HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and maintains $5 price target.
HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.10...
HC Wainwright & Co. analyst Arthur He maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and lowers the price target from...